Immutrin, a British biotech company based in Cambridge, England, secured $86 million in funding to advance its antibody drug program. The therapy is designed to deplete protein deposits in patients with amyloidosis, a rare disease characterized by abnormal protein buildup in organs and tissues.
The company was co-founded by Gregory Winter, a Nobel Prize-winning scientist known for his work in antibody engineering. Amyloidosis affects thousands of patients worldwide and can be life-threatening when protein deposits accumulate in vital organs like the heart and kidneys.